Thousand Oaks -- Amgen (NASDAQ:AMGN) will hold an investor webcast on Saturday, October 24, 2026, at 11:30 a.m. PT to discuss its oncology portfolio and selected data presented at the European Society of Medical Oncology Congress (ESMO) 2026.

Two senior executives lead Amgen's ESMO 2026 investor call

Murdo Gordon, executive vice president of Global Markets and Policy, and Jean-Charles Soria, senior vice president of oncology within Global Development, will lead the session. Other members of Amgen's management team will also take part.

Global – October 20, 2026 -- The International Society for Cell & Gene Therapy (ISCT) has made cold-chain readiness a specific focus for 2026, and SpotSee is outlining how shippers can match temperature-monitoring technology to the evidence their quality teams need.

San Sebastián – – October 19, 2026 -- Viralgen, the AAV gene therapy contract manufacturer owned by Bayer unit AskBio, has appointed Bayer executive Angela Ochoa Chico as chief executive effective January 1, 2027, replacing Jimmy Vanhove after four years in the role.

Vanhove moves to lead Bayer's U.S. pharmaceutical supply network expansion

Vanhove will lead the development and expansion of Bayer's U.S. Pharmaceutical Product Supply Network, based in New Albany, Ohio. He will join the Pharmaceuticals Division's Product Supply Leadership Team.

Bridgewater – – October 19, 2026 -- Insmed (Nasdaq: INSM) has launched BRINSUPRI Tablets 25 mg (brensocatib hydrate) in Japan, making it the first and only approved, commercially available treatment for non-cystic fibrosis bronchiectasis (NCFB) in the country.

Japan's health ministry cleared the once-daily oral tablet in August 2026

The Ministry of Health, Labour, and Welfare approved BRINSUPRI based on results from the Phase 3 ASPEN study. The label covers adults and pediatric patients aged 12 years and older.

San Diego – October 19, 2026 -- The U.S. Food and Drug Administration has cleared Protego Biopharma's Investigational New Drug application for PROT-001, allowing the company to start SHIELD-AL, a global pivotal Phase 2/3 study in newly diagnosed light chain (AL) amyloidosis patients.

PROT-001 is an oral, investigational, first-in-class lambda light chain stabilizer. Protego will test it as an add-on to standard-of-care plasma cell-directed therapy, which reduces light chain production.

Suzhou – October 19, 2026 -- MegaRobo Technologies has launched Poreva Open, a global AI protein design competition that will put more than 10,000 designs through standardized wet-lab experiments and offers US$250,000 in cash prizes.

San Diego – October 19, 2026 -- Capricor Therapeutics (NASDAQ: CAPR) disputed the post-hoc analyses in the FDA's briefing materials, two days before an advisory committee meets on July 29 to discuss its Biologics License Application (BLA) for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD).

San Diego – October 19, 2026 -- Capricor Therapeutics (NASDAQ: CAPR) ended the second quarter with about $237.9 million in cash, cash equivalents and marketable securities, down from about $318.1 million at Dec. 31, 2025. The decline came as an FDA advisory committee voted 9 against and 3 in favor on whether evidence shows Deramiocel is effective for cardiomyopathy in Duchenne muscular dystrophy (DMD) patients.

San Diego – October 19, 2026 -- Capricor Therapeutics (NASDAQ: CAPR) reported that Duchenne muscular dystrophy patients who switched from placebo to Deramiocel after one year slowed their upper limb decline by 76% compared with their own prior year, according to open-label extension data from the Phase 3 HOPE-3 trial. The U.S. FDA has set a PDUFA target action date of November 22, 2026, for the therapy.

Indianapolis – October 19, 2026 -- Half of pediatric ulcerative colitis (UC) patients who responded to Eli Lilly's Omvoh (mirikizumab-mrkz) were in clinical remission at Week 52, meeting the primary endpoint of the Phase 3 SHINE-2 study. Lilly (NYSE: LLY) says Omvoh is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric UC, and it plans to submit the data to global regulators for a potential label expansion.